Liru He1, Andrew Chapple2, Zhongxing Liao3, Ritsuko Komaki3, Peter F Thall4, Steven H Lin5. 1. Department of Radiation Oncology, Sun Yat-Sun University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 2. Department of Statistics, Rice University, Houston, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: rex@mdanderson.org. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: shlin@mdanderson.org.
Abstract
BACKGROUND AND PURPOSE: To evaluate radiation modality effects on pericardial effusion (PCE), pleural effusion (PE) and survival in esophageal cancer (EC) patients. MATERIALS AND METHODS: We analyzed data from 470 EC patients treated with definitive concurrent chemoradiotherapy (CRT). Bayesian semi-competing risks (SCR) regression models were fit to assess effects of radiation modality and prognostic covariates on the risks of PCE and PE, and death either with or without these preceding events. Bayesian piecewise exponential regression models were fit for overall survival, the time to PCE or death, and the time to PE or death. All models included propensity score as a covariate to correct for potential selection bias. RESULTS: Median times to onset of PCE and PE after RT were 7.1 and 6.1months for IMRT, and 6.5 and 5.4months for 3DCRT, respectively. Compared to 3DCRT, the IMRT group had significantly lower risks of PE, PCE, and death. The respective probabilities of a patient being alive without either PCE or PE at 3-years and 5-years were 0.29 and 0.21 for IMRT compared to 0.13 and 0.08 for 3DCRT. In the SCR regression analyses, IMRT was associated with significantly lower risks of PCE (HR=0.26) and PE (HR=0.49), and greater overall survival (probability of beneficial effect (pbe)>0.99), after controlling for known clinical prognostic factors. CONCLUSIONS: IMRT reduces the incidence and postpones the onset of PCE and PE, and increases survival probability, compared to 3DCRT.
BACKGROUND AND PURPOSE: To evaluate radiation modality effects on pericardial effusion (PCE), pleural effusion (PE) and survival in esophageal cancer (EC) patients. MATERIALS AND METHODS: We analyzed data from 470 EC patients treated with definitive concurrent chemoradiotherapy (CRT). Bayesian semi-competing risks (SCR) regression models were fit to assess effects of radiation modality and prognostic covariates on the risks of PCE and PE, and death either with or without these preceding events. Bayesian piecewise exponential regression models were fit for overall survival, the time to PCE or death, and the time to PE or death. All models included propensity score as a covariate to correct for potential selection bias. RESULTS: Median times to onset of PCE and PE after RT were 7.1 and 6.1months for IMRT, and 6.5 and 5.4months for 3DCRT, respectively. Compared to 3DCRT, the IMRT group had significantly lower risks of PE, PCE, and death. The respective probabilities of a patient being alive without either PCE or PE at 3-years and 5-years were 0.29 and 0.21 for IMRT compared to 0.13 and 0.08 for 3DCRT. In the SCR regression analyses, IMRT was associated with significantly lower risks of PCE (HR=0.26) and PE (HR=0.49), and greater overall survival (probability of beneficial effect (pbe)>0.99), after controlling for known clinical prognostic factors. CONCLUSIONS: IMRT reduces the incidence and postpones the onset of PCE and PE, and increases survival probability, compared to 3DCRT.
Authors: Anurag Chandra; Thomas M Guerrero; H Helen Liu; Susan L Tucker; Zhongxing Liao; Xiaochun Wang; Hasan Murshed; Mark D Bonnen; Amit K Garg; Craig W Stevens; Joe Y Chang; Melinda D Jeter; Radhe Mohan; James D Cox; Ritsuko Komaki Journal: Radiother Oncol Date: 2005-11-17 Impact factor: 6.280
Authors: K Hayashi; Y Fujiwara; M Nomura; M Kamata; H Kojima; M Kohzai; K Sumita; N Tanigawa Journal: Br J Radiol Date: 2014-11-27 Impact factor: 3.039
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-03 Impact factor: 7.038
Authors: Charles S Mayo; Marcia M Urie; Thomas J Fitzgerald; Linda Ding; Yuan Chyuan Lo; Madeleine Bogdanov Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-11 Impact factor: 7.038